Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Nasdaq 100, S&P 500, Microsoft Corporation, SPDR® S&P 500. Read Contrarian Outlook (Brett Owens)'s latest article on Investing.com ...

Hoya Capital High Dividend Yield ETF offers a diversified portfolio of mostly higher-yielding REITs. Click here to read why ...

Morningstar research reveals what's holding some advisors back, and which providers are leading the way in responding.

Frec, the innovative investment platform known for redefining direct indexing, today announces the launch of its Portfolio ...

With expertise in strategic asset allocation, quantitative modeling, macro and fundamental research, technical research, and ...

Tax and Legal Optimization: Strong pre-tax returns can be undermined by poor tax planning. Advisors assist with structuring ...

Kellogg’s is on a mission to reaffirm its seat at the breakfast table, and is leaning into its previously “under-leveraged” ...

For most active investment managers, the goal is clear: to achieve consistently strong, long-term outperformance in any ...

Tetra Tech , Inc. (NASDAQ:TTEK), a leading provider of consulting and engineering services, has recently been the subject of ...

Leeford Healthcare, a trusted pharmaceutical brand with India's 2nd-largest product portfolio and a legacy spanning almost ...

Invest in SPDR S&P Biotech ETF (XBI) for long-term growth potential and diverse, equal-weighted portfolio in the biotech ...